Skip to main content

Advertisement

Table 2 Drug treatment

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

  Medication n (%)
Total number of patients 3316
Concomitant administration of lipid-lowering drug during the study  
No concomitant drug 3149 (95.0%)
Concomitant administration 167 (5.0%)
   statin   119 (3.6%)
   others   48 (1.4%)
diabetes drug administration before and during the study  
   -Before- -During-  
   Not taken Not taken 818 (24.7%)
   Not taken Taken 521 (15.7%)
   Taken Not taken 106 (3.2%)
   Taken Taken 1871 (56.4%)
No concomitant diabetes drug during the study 924 (27.9%)
Concomitant treatment with diabetes drug during the study 2392 (72.1%)
Single treatment with:  
   Sulfonylurea   732 (22.1%)
   Glinide   188 (5.7%)
   Alpha-glucosidase inhibitor   169 (5.1%)
   Biguanide   93 (2.8%)
   Thiazolidine   49 (1.5%)
   Insulin   156 (4.7%)
Combination therapies:  
   Sulfonylurea + alpha-glucosidase inhibitor   229 (6.9%)
   Sulfonylurea + biguanide   212 (6.4%)
   Sulfonylurea + thiazolidine   91 (2.7%)
   Other   473 (14.3%)